SG Americas Securities LLC Sells 322,780 Shares of Sarepta Therapeutics, Inc. $SRPT

SG Americas Securities LLC decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 62.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 191,371 shares of the biotechnology company’s stock after selling 322,780 shares during the quarter. SG Americas Securities LLC’s holdings in Sarepta Therapeutics were worth $4,118,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SRPT. Vanguard Group Inc. raised its holdings in shares of Sarepta Therapeutics by 18.1% during the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares in the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after buying an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Sarepta Therapeutics by 183.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after acquiring an additional 1,129,610 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in shares of Sarepta Therapeutics by 65.7% in the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after acquiring an additional 1,064,530 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in Sarepta Therapeutics by 347.8% in the second quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after acquiring an additional 1,016,069 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised their price objective on Sarepta Therapeutics from $12.00 to $14.00 and gave the company a “sell” rating in a research note on Thursday, March 26th. Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, Mizuho upped their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $32.59.

Sarepta Therapeutics Trading Up 5.0%

NASDAQ SRPT opened at $23.23 on Friday. The company’s 50-day simple moving average is $18.73 and its two-hundred day simple moving average is $20.11. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $64.80. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -2.75, a price-to-earnings-growth ratio of 0.34 and a beta of 0.29. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The business’s quarterly revenue was down 32.7% on a year-over-year basis. During the same period last year, the firm earned $1.90 EPS. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.